甲胺增加了基因组脱乙酶1,3,和8表达,作为2型糖尿病患者表观遗传调节剂
相关实验视频
Updated: Jan 15, 2026

09:11
Assays for Validating Histone Acetyltransferase Inhibitors
Published on: August 6, 2020
7.0K
Amin Izadi1, Azam Zarourati1, Sohrab Boozarpour1
1Department of Biology, Faculty of Basic Sciences, Gonbad Kavous University, Gonbad Kavous, Golestan, Iran.
Reports of biochemistry & molecular biology
|January 14, 2026
概括
在2型糖尿病患者中,甲胺治疗增加了某些基因的表达. 肥胖也增加了HDAC基因表达,这表明HDACs是糖尿病管理的潜在治疗点.
科学领域:
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 分子生物学分子生物学
- 内分泌学 在内分泌学.
背景情况:
- 2型糖尿病是一种复杂的代谢障碍,受遗传,表观遗传和环境因素的影响.
- 基因组脱乙酶 (HDACs) 是关键的表观遗传调节剂,参与了代谢平衡和β细胞功能,影响糖尿病的发展和治疗.
- 作为一种主要的2型糖尿病疗法,甲福明被研究其对I类HDAC基因表达的影响.
研究的目的:
- 为了研究甲胺对I类HDAC基因表达在2型糖尿病中的影响.
- 为了检查肥胖和I类HDAC基因表达之间的关系.
- 确定2型糖尿病中潜在的表观遗传生物标志物和治疗点.
主要方法:
- 一项涉及120名受试者的研究,包括60名2型糖尿病患者 (接受甲福明治疗与未接受治疗) 和60名正常耐葡萄糖个体 (肥胖者与非肥胖者).
- 使用标准方法对生化和临床因素的定量评估.
- 逆转录定量聚合酶链反应 (RT-qPCR) 用于测量外围血液单核细胞中的I类HDAC基因表达.
主要成果:
- 甲胺治疗显著增加了HDAC1,HDAC3和HDAC8.8的表达.
- 与非肥胖个体相比,肥胖与HDAC1,HDAC2和HDAC3的表达水平更高有关.
- 在I类HDAC基因表达和糖尿病相关风险因素之间发现了显著的相关性.
结论:
- 甲福明会影响HDAC1,HDAC3和HDAC8基因的表达.
- 肥胖显著增加糖尿病的风险,部分是通过其对HDAC表达的影响.
- HDAC基因表达的变化可以作为2型糖尿病的生物标志物和治疗点,特别是在与甲胺的联合治疗中.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
582
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
582
Dipeptidyl Peptidase 4 Inhibitors
581
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
581
Histone Modification
15.9K
The histone proteins have a flexible N-terminal tail extending out from the nucleosome. These histone tails are often subjected to post-translational modifications such as acetylation, methylation, phosphorylation, and ubiquitination. Particular combinations of these modifications form “histone codes” that influence the chromatin folding and tissue-specific gene expression.
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone...
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone...
15.9K
Histone Modification
4.4K
4.4K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
522
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
522
Diabetes Mellitus: Type 2 and Gestational
4.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.3K

